Crinetics Pharmaceuticals Inc
Fechado
SetorSaúde
84.95 0.13
Visão Geral
Variação de preço das ações
24h
Mín
84.95
Máximo
84.95
Rendimento | 7M -121M |
|---|---|
Vendas | 14M 25M |
EPS | -1.14 |
Margem de lucro | -481.149 |
Funcionários | 594 |
EBITDA | -4.7M -131M |
Recomendações | Neutro |
|---|---|
Previsão para 12 meses | +0.72% upside |
Capitalização de Mercado | 148M 9B |
|---|---|
Abertura anterior | 84.82 |
Fecho anterior | 84.95 |
Crinetics Pharmaceuticals Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Crinetics Pharmaceuticals Inc Previsão
Preço-alvo
By TipRanks
0.72% parte superior
Previsão para 12 meses
Média 85.56 USD 0.72%
Máximo 95 USD
Mínimo 80 USD
Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.
Informação Financeira
$
Sobre Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
